Logo

Qiagen Targeted RNA Panels

Feb 11, 2016

Qiagen has launched more than 170 new QIAseq targeted RNA panels for gene expression profiling. The panels enable researchers to select from over 20,000 human genes and IncRNA to survey expression fold changes and discover interactions between genes, cellular phenotypes, and disease processes, said the company. The panel technology combines the flexibility and throughput of NGS with the accuracy of qPCR and uses only 20 nanograms of starting RNA material to analyze hundreds of genes. QIAseq targeted RNA panels cover an extensive range of disease- and signaling pathway-focused genes, with each panel targeting 100 to 500 genes. The panels can also be customized to include other genes of clinical and biological interest with the flexibility to analyze from 12 to 1,000 genes simultaneously.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.